Cargando…

Future of Monoclonal Antibody Therapy in Parkinson’s Disease

Detalles Bibliográficos
Autores principales:	Kharel, Sanjeev, Ojha, Rajeev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259150/ https://www.ncbi.nlm.nih.gov/pubmed/37313331 http://dx.doi.org/10.1177/09727531221136349

Ejemplares similares

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
por: Ascierto, Paolo A, et al.
Publicado: (2011)

Salivary alpha‐synuclein as a potential fluid biomarker in Parkinson’s disease: A systematic review and meta‐analysis
por: Kharel, Sanjeev, et al.
Publicado: (2022)

From a Parkinson's disease expert: Rasagiline and the Future of Therapy
por: Lakhan, Shaheen E
Publicado: (2007)

Developing Monoclonal Antibodies for Immunohistochemistry
por: Cordell, Jacqueline
Publicado: (2022)

Levetiracetam versus Oxcarbazepine as monotherapy in newly diagnosed focal epilepsy: A systematic review and meta‐analysis
por: Kharel, Sanjeev, et al.
Publicado: (2022)

The Combination of Dupilumab with Other Monoclonal Antibodies
por: Gisondi, P., et al.
Publicado: (2022)

Monoclonal Antibodies and Flaviviruses: a Possible Option?
por: Mancini, Nicasio
Publicado: (2022)

Switching to Tenecteplase from Alteplase for Ischemic Stroke: Is it the Time for Universal Adoption?
por: Kharel, Sanjeev, et al.
Publicado: (2022)

The dangers of mass drug administration of albendazole in Nepal, a Neurocysticercosis-endemic region
por: Nepal, Gaurav, et al.
Publicado: (2020)

Back to the future: new target-validated Rab antibodies for evaluating LRRK2 signalling in cell biology and Parkinson's disease
por: Eyers, Patrick A.
Publicado: (2018)

Immunocytochemical Labelling of Haematological Samples Using Monoclonal Antibodies
por: Erber, Wendy N.
Publicado: (2021)

Commentary: Engineering antibody therapies may be the future of therapeutics
por: Akhmerov, Akbarshakh, et al.
Publicado: (2021)

C‐reactive protein levels in patients with amyotrophic lateral sclerosis: A systematic review
por: Kharel, Sanjeev, et al.
Publicado: (2022)

iBreastExam: Time for Formal Operation in Nepal
por: Kharel, Sanjeev, et al.
Publicado: (2022)

Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?
por: Eccles, Suzanne A
Publicado: (2001)

EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
por: Francescon, Sara, et al.
Publicado: (2018)

Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis
por: Kharel, Sanjeev, et al.
Publicado: (2021)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
por: Martelletti, Paolo
Publicado: (2020)

Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?
por: Jalalizadeh, Mehrsa, et al.
Publicado: (2023)

Broadly neutralizing monoclonal antibodies for HIV prevention
por: Miner, Maurine D., et al.
Publicado: (2021)

Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?
por: Musto, Pellegrino
Publicado: (2018)

The status and future of emergency care in the Republic of Kenya
por: Lee, J. Austin, et al.
Publicado: (2022)

The understanding of Parkinson's disease through genetics and new therapies
por: Uwishema, Olivier, et al.
Publicado: (2022)

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
por: Landgren, Ola, et al.
Publicado: (2023)

Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
por: Gambale, Elisabetta, et al.
Publicado: (2022)

Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease
por: Hwu, Paul Wuh‐Liang, et al.
Publicado: (2021)

Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al
por: Dixon, Will, et al.
Publicado: (2006)

Updates for Health Providers on Monoclonal Antibodies for COVID-19: Less Promising Adjunct and Never an Alternative to Vaccinations
por: Berges, Maja, et al.
Publicado: (2022)

Are Stem Cell-Based Therapies for Parkinson’s Disease Ready for the Clinic in 2016?
por: Barker, Roger A., et al.
Publicado: (2016)

SARS-CoV-2 Monoclonal Antibodies in Children: Ethical Considerations
por: Wolfe, Ian D., et al.
Publicado: (2021)

One Against All: A Broadly Influenza Neutralizing Man-made Monoclonal Antibody Passes Phase I
por: Saelens, Xavier
Publicado: (2016)

Monoclonal Antibodies in Multiple Sclerosis: Present and Future
por: Voge, Natalia V., et al.
Publicado: (2019)

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use
por: Sparrow, Erin, et al.
Publicado: (2022)

Monoclonal antibody-based therapies for microbial diseases
por: Saylor, Carolyn, et al.
Publicado: (2009)

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
por: Pierpont, Timothy M., et al.
Publicado: (2018)

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
por: Casadevall, Arturo, et al.
Publicado: (2023)

Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future
por: Prins, Niels D, et al.
Publicado: (2013)

Antidotes, antibody-mediated immunity and the future of pharmaceutical product development
por: Caoili, Salvador Eugenio C.
Publicado: (2013)

Monoclonal antibodies for imaging and therapy.
por: Epenetos, A. A., et al.
Publicado: (1989)

Monoclonal antibodies for the therapy of cancer
por: Simpson, Andrew, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_llt6psqdnv88d6lam83r5p1hgr